Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 4, 2013, Pages 450-466

  Bhave, Prashant D ^a   Knight, Bradley P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Atrial flutter; Bleeding; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; RIVAROXABAN; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CARDIAC IMAGING; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEALTH CARE PLANNING; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; INTRACARDIAC THROMBOSIS; LOW DRUG DOSE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PATIENT SAFETY; POSTOPERATIVE HEMORRHAGE; PROCESS OPTIMIZATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT CONTRAINDICATION;

EID: 84881083732     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-013-0242-9     Document Type: Review

References (57)

1. Kneeland PP, Fang MC. Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med. 2009;4:E1-5.
2. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9:632-696 e21.
3. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42:1493-531.
4. Prudente LA, Moorman JR, Lake D, et al. Femoral vascular complications following catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2009;26:59-64.
5. Hoyt H, Bhonsale A, Chilukuri K, et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm. 2011;8:1869-74.
6. Aldhoon B, Wichterle D, Peichl P, Cihak R, Kautzner J. Complications of catheter ablation for atrial fibrillation in a high-volume centre with the use of intracardiac echocardiography. Europace. 2013;15(1):24-32.
7. Chierchia GB, Capulzini L, Droogmans S, et al. Pericardial effusion in atrial fibrillation ablation: a comparison between cryoballoon and radiofrequency pulmonary vein isolation. Europace. 2010;12:337-41.
8. Abhishek F, Heist EK, Barrett C, et al. Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2011;30:211-5.
9. Sakurai K, Hirai T, Nakagawa K, et al. Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter. Chest. 2003;124:1670-4.
10. Ru San T, Chan MY, Wee Siong T, et al. Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis. 2012;2012:108983.
11. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology. 2012;79:1428-34.
12. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012;43:881-3.
13. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110:845-51.
14. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-70.
15. Manolis AS, Melita-Manolis H, Vassilikos V, et al. Thrombogenicity of radiofrequency lesions: results with serial D-dimer determinations. J Am Coll Cardiol. 1996;28:1257-61.
16. Dorbala S, Cohen AJ, Hutchinson LA, Menchavez-Tan E, Steinberg JS. Does radiofrequency ablation induce a prethrombotic state? Analysis of coagulation system activation and comparison to electrophysiologic study. J Cardiovasc Electrophysiol. 1998;9:1152-60.
17. Anfinsen OG, Gjesdal K, Brosstad F, et al. The activation of platelet function, coagulation, and fibrinolysis during radiofrequency catheter ablation in heparinized patients. J Cardiovasc Electrophysiol. 1999;10:503-12.
18. Saad EB, Costa IP, Costa RE, et al. Safety of ablation for atrial fibrillation with therapeutic INR: comparison with transition to low-molecular-weight heparin. Arq Bras Cardiol. 2011;97:289-96.
19. Santangeli P, Di Biase L, Sanchez JE, Horton R, Natale A. Atrial fibrillation ablation without interruption of anticoagulation. Cardiol Res Pract. 2011;2011:837841.
20. Hussein AA, Martin DO, Saliba W, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm. 2009;6:1425-9.
21. Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116:2531-4. Retrospective study showing that performing AF ablation with a therapeutic INR is safe.
22. Finlay M, Sawhney V, Schilling R, et al. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy. J Cardiovasc Electrophysiol. 2010;21:150-4. Prospective non-randomized study showing that performing AFL ablation with a therapeutic INR is safe.
23. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation. 2010;121:2550-6. Retrospective study demonstrating the safety of performing AF ablation with a therapeutic INR.
24. Gautam S, John RM, Stevenson WG, et al. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:248-54.
25. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59:1168-74. Case-control study showing that nearly uninterrupted dabigatran is associated with more bleeding complications with AF ablation.
26. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm. 2012;69:1473-84.
27. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9.
28. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012;119:2172-4.
29. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs Warfarin for Radiofrequency Catheter Ablation of Atrial Fibrillation. Heart Rhythm. 2012. doi: 10.1016/j.hrthm.2012.12.011
30. Asbach S, Biermann J, Bode C, Faber TS. Early heparin administration reduces risk for left atrial thrombus formation during atrial fibrillation ablation procedures. Cardiol Res Pract. 2011;2011:615087.
31. Chilukuri K, Henrikson CA, Dalal D, et al. Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2009;25:175-81.
32. Parodi G, De Luca G, Moschi G, et al. Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. J Thromb Thrombolysis. 2010;30:446-51.
33. Stone DH, Nolan BW, Schanzer A, et al. Protamine reduces bleeding complications associated with carotid endarterectomy without increasing the risk of stroke. J Vasc Surg. 2010;51:559-64, 64 e1
34. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol. 2012;35:29-33.
35. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23:264-8. Retrospective study demonstrating that use of dabigatran within a day of AF ablation is safe
36. Khairy P, Chauvet P, Lehmann J, et al. Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation. Circulation. 2003;107:2045-50.
37. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. RELY study showing non-inferiority of dabigatran to warfarin in patients with non-valvular AF.
38. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. ROCKET-AF study showing non-inferiority of rivaroxaban to warfarin in patients with non-valvular AF.
39. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17. ARISTOTLE study showing superiority of apixaban to warfarin in patients with non-valvular AF.
40. Wasmer K, Kobe J, Dechering D, et al. CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. Clin Res Cardiol 2012.
41. Smith SA, Binkley PF, Foraker RE, Nagaraja HN, Orsinelli DA. The role of repeat transesophageal echocardiography in patients without atrial thrombus prior to cardioversion or ablation. J Am Soc Echocardiogr. 2012;25:1106-12.
42. Calvo N, Mont L, Vidal B, et al. Usefulness of transoesophageal echocardiography before circumferential pulmonary vein ablation in patients with atrial fibrillation: is it really mandatory? Europace. 2011;13:486-91. Retrospective study examining the importance of obtaining a TEE prior to AF ablation.
43. Yamashita E, Takamatsu H, Tada H, et al. Transesophageal echocardiography for thrombus screening prior to left atrial catheter ablation. Circ J. 2010;74:1081-6.
44. McCready JW, Nunn L, Lambiase PD, et al. Incidence of left atrial thrombus prior to atrial fibrillation ablation: is pre-procedural transoesophageal echocardiography mandatory? Europace. 2010;12:927-32.
45. Gula LJ, Massel D, Redfearn DP, et al. Impact of routine transoesophageal echocardiography on safety, outcomes, and cost of pulmonary vein ablation: inferences drawn from a decision analysis model. Europace. 2010;12:1550-7.
46. Ren JF, Marchlinski FE, Supple GE, et al. Intracardiac Echocardiographic Diagnosis of Thrombus Formation in the Left Atrial Appendage: A Complementary Role to Transesophageal Echocardiography. Echocardiography. 2013;30(1):72-80.
47. Dorenkamp M, Sohns C, Vollmann D, et al. Detection of left atrial thrombus during routine diagnostic work-up prior to pulmonary vein isolation for atrial fibrillation: Role of transesophageal echocardiography and multidetector computed tomography. Int J Cardiol 2011.
48. Patel A, Au E, Donegan K, et al. Multidetector row computed tomography for identification of left atrial appendage filling defects in patients undergoing pulmonary vein isolation for treatment of atrial fibrillation: comparison with transesophageal echocardiography. Heart Rhythm. 2008;5:253-60.
49. Hur J, Kim YJ, Lee HJ, et al. Cardioembolic stroke: dual-energy cardiac CT for differentiation of left atrial appendage thrombus and circulatory stasis. Radiology. 2012;263:688-95.
50. Kapa S, Martinez MW, Williamson EE, et al. ECG-gated dual-source CT for detection of left atrial appendage thrombus in patients undergoing catheter ablation for atrial fibrillation. J Interv Card Electrophysiol. 2010;29:75-81.
51. Bunch TJ, Crandall BG, Weiss JP, et al. Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol. 2009;20:988-93.
52. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55:735-43.
53. Daoud EG, Glotzer TV, Wyse DG, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm. 2011;8:1416-23.
54. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72. The study that defined the use of the CHADS2-VASc score for the estimation of stroke risk in AF.
55. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70. The study that defined the use of the CHADS2 score for the estimation of stroke risk in AF.
56. Chinitz JS, Gerstenfeld EP, Marchlinski FE, Callans DJ. Atrial fibrillation is common after ablation of isolated atrial flutter during long-term follow-up. Heart Rhythm. 2007;4:1029-33.
57. Ellis K, Wazni O, Marrouche N, et al. Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2007;18:799-802.